Citius Pharmaceuticals, Inc. Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)
Citius Pharmaceuticals, Inc. (CTXR) reported Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) of $452.15 thousand for the 12-month period ending 2017-09-30, per its 10-K filed 2019-12-16.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2019-12-16
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-09-30 was $143.27K, a 82.56% decline year-over-year.
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-06-30 was -$133.51K.
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-03-31 was -$179.80K.
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-12-31 was $622.19K, a 2498.94% increase year-over-year.
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2017 was $452.15K.
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2016 was -$838.22K, a 352.40% decline from fiscal 2015.
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2015 was $332.10K, a 3766.97% increase from fiscal 2014.
- Citius Pharmaceuticals, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2014 was $8.59K.
| Period end | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2017-09-30 | $143.27K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-16 | $9.76K derived: sum of 2 quarters · filed 2019-12-16 | -$170.04K derived: sum of 3 quarters · filed 2019-12-16 | $452.15K 10-K · filed 2019-12-16 |
| 2017-06-30 | -$133.51K 10-Q · filed 2018-08-14 | -$313.31K derived: sum of 2 quarters · filed 2018-08-14 | $308.88K 10-Q · filed 2018-08-14 | $1.13M derived: sum of 4 quarters · filed 2018-12-11 |
| 2017-03-31 | -$179.80K 10-Q · filed 2018-05-11 | $442.39K 10-Q · filed 2018-05-11 | $1.26M derived: sum of 3 quarters · filed 2018-12-11 | -$221.92K derived: sum of 4 quarters · filed 2018-12-11 |
| 2016-12-31 | $622.19K 10-Q · filed 2018-02-14 | $1.44M derived: sum of 2 quarters · filed 2018-12-11 | -$42.13K derived: sum of 3 quarters · filed 2018-12-11 | -$239.97K derived: sum of 4 quarters · filed 2018-12-11 |
| 2016-09-30 | $821.52K derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11 | -$664.31K derived: sum of 2 quarters · filed 2018-12-11 | -$862.16K derived: sum of 3 quarters · filed 2018-12-11 | -$838.22K 10-K · filed 2018-12-11 |
| 2016-06-30 | -$1.49M 10-Q · filed 2017-08-14 | -$1.68M derived: sum of 2 quarters · filed 2017-08-14 | -$1.66M 10-Q · filed 2017-08-14 | -$1.60M derived: sum of 4 quarters · filed 2017-12-13 |
| 2016-03-31 | -$197.85K 10-Q · filed 2017-05-15 | -$173.91K 10-Q · filed 2017-05-15 | -$113.96K derived: sum of 3 quarters · filed 2017-12-13 | -$165.50K derived: sum of 4 quarters · filed 2017-12-13 |
| 2015-12-31 | $23.94K 10-Q · filed 2017-02-14 | $83.89K derived: sum of 2 quarters · filed 2017-12-13 | $32.35K derived: sum of 3 quarters · filed 2017-12-13 | |
| 2015-09-30 | $59.95K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-13 | $8.41K derived: sum of 2 quarters · filed 2017-12-13 | $332.10K 10-K · filed 2017-12-13 | |
| 2015-06-30 | -$51.54K 10-Q · filed 2016-08-15 | $272.15K 10-Q · filed 2016-08-15 | ||
| 2014-09-30 | $8.59K 10-K · filed 2016-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |